Click through these 5 statements about the "gliflozin" class of diabetes drugs for a test of your recall and retention.
The sodium glucose cotransporter-2 inhibitor class of antihyperglycemic agents are proven both safe and effective in treating type 2 diabetes. What do you know about details of registration trials and post-marketing research on the "gliflozins?"Use this first installment of 5 True/False statements above to test your recall and retention.Links for additional information provided below and in slide captions.Â Â References1. FDA approves SGLT2 inhibitor STEGLATROâ¢ (ertugliflozin) and fixed-dose combination STEGLUJANâ¢ (ertugliflozin and sitagliptin) for adults with type 2 diabetes [press release]. New York: Pfizer Inc; December 22, 2017.Â Accessed January 22 2018. :2. Pinto LC, Rados DV, Remonti LR, et al. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. Diabetol Metab Syndr. 2015;7: A58. Published online November 11, 2015. doi:Â 10.1186/1758-5996-7-S1-A58.3. Zinman B, Wanner C ,Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi: 10.1056/NEJMoa1504720.4. Zhang XL, Zhu QQ, Yu-Han C, et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and meta-analysis with trial sequential analysis.Â J Am Heart Assoc. 2018;7:e007165. DOI: 10.1161/JAHA.117.0071655. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) [FDA Drug Safety Communication]. May 16 2017.Â Accessed January 22, 2018.
True or False? 5 statements about sodium glucose contransporter-2 inhibitors and the research that supports them.
FALSE: In December 2017, ertugliflozin, (STEGLATRO™ co-developed by Merck and Pfizer) became the fourth SGLT2 inhibitor approved by the US Food and Drug Administration.1
TRUE. A recent meta-analysis of 39 randomized controlled trials found that, compared to placebo, SGLT2 inhibitors are associated with 0.5-1% reduction in HbA1c.2
3. Even though studies suggest SGLT2 inhibitors may improve cardiovascular outcomes, drugs in this class are not FDA approved for CV risk reduction. True or false?
FALSE. In December 2016, empagliflozin became the first antidiabetes drug to receive regulatory approval for CV risk reduction.3
4. SGLT2 inhibitors are associated with a decrease in systolic and diastolic blood pressure. True or false?
TRUE. According to a recent meta-analysis of 11 studies, SGLT2 inhibitors are associated with a decrease in systolic blood pressure of about -3.84 mm Hg, and a decrease in diastolic blood pressure of about -1.03 mm Hg.4
TRUE. In May 2017, the FDA placed a boxed warning on the label of canagliflozin because of evidence suggesting increased risk of leg and foot amputations,5 an action taken based on findings from the CANVAS and CANVAS-R studies.